Prescription Drug Affordability Boards and Cystic Fibrosis

States are increasingly using prescription drug affordability boards to address the cost of prescription drugs to both the state and the consumer.

3 min read
Summary
  • In response to rising prescription drug costs and their impact on health care spending, some states have established prescription drug affordability boards to review certain high-cost prescription drugs and determine if states should take action to reduce those costs.
  • The primary function of the boards is to reduce government and commercial market spending on prescription drugs and increase affordability for patients.
  • Preserving access to care and treatments for people with CF remains the Foundation’s paramount goal. We do this by sharing evidence about the benefits of CF therapies and encouraging review boards to put those living with CF at the center of these deliberations.  

In response to rising prescription drug costs and their impact on health care spending, some states have established prescription drug affordability boards (PDABs) to assess the price and affordability of certain high-cost medications and determine if states should take action to reduce those costs. The primary function of these boards is to reduce government and commercial spending on prescription drugs and lower the price of prescription drugs for patients.

Prescription Drug Affordability Boards’ Review of CF Medicines

States vary in how they define affordability and select and review drugs; states also have different authorities to take action to address affordability. As a patient advocacy organization, the CF Foundation focuses on ensuring state boards understand the overall value of a prescription drug for people with CF. We do this by providing evidence about the clinical benefit of a therapy, including the impact on long-term health and well-being and how treatments affect other aspects of CF care. We also help identify opportunities for stakeholders, such as community members, caregivers, researchers, and providers, to share their experiences and insights about a drug’s impact.

In 2023, Colorado became the first state to assess the affordability of elexacaftor/tezacaftor/ivacaftor (Trikafta) through a prescription drug affordability board. The board ultimately decided that Trikafta is not unaffordable for Colorado consumers, citing extensive information received from patients, caregivers, clinicians, and other stakeholders. To date, no other state board has selected a CFTR modulator for an affordability review, though other symptomatic treatments, such as pancreatic enzymes, have been considered but ultimately not selected.

Our Position on Prescription Drug Affordability Boards

The Foundation’s priority is people with cystic fibrosis and safeguarding their access to medications to keep them healthy. We are committed to being key advisors to state boards to ensure they understand a modulator’s role in extending the lives of many in the CF community.

The Foundation engages with PDABs and state policymakers to ensure that any discussions about prescription drug pricing center on patient access. This includes asking PDABs to:

  • Engage patients, their caregivers, and providers throughout the review process
  • Be transparent about their selection and review processes and how patient data will be used
  • Consider the availability of therapeutic alternatives, orphan drug status, and length of time on the market when selecting and reviewing drugs
  • Explore other policy solutions to address drug affordability beyond upper payment limits

Read more about our work with prescription drug affordability boards.

Share this article
Join Us in Advocating for People With Cystic Fibrosis

Sign up for advocacy alerts by texting “FIGHTCF” to 96387 to join a list of volunteer advocates.  

*Message and data rates may apply. Reply STOP to opt out, HELP for help.

Sign up today